These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 26345996)

  • 1. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
    Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
    J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.
    Lee BS; Kang S; Kim KA; Song YJ; Cheong KH; Cha HY; Kim CH
    Cell Death Dis; 2014 Apr; 5(4):e1159. PubMed ID: 24722284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.
    Zillhardt M; Christensen JG; Lengyel E
    Neoplasia; 2010 Jan; 12(1):1-10. PubMed ID: 20072648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.
    Lau PC; Wong EY
    Pathol Oncol Res; 2012 Apr; 18(2):357-63. PubMed ID: 21866424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
    Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
    Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
    Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
    Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma.
    Zhang J; Jiang Y; Yu Y; Li J
    Eur J Pharmacol; 2022 Jan; 915():174688. PubMed ID: 34883074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
    Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
    Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma.
    Xie LQ; Bian LJ; Li Z; Li Y; Li ZX; Li B
    Ann Surg Oncol; 2010 Jul; 17(7):1927-36. PubMed ID: 20131016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolfenamic Acid Inhibits the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma: Involvement of p38-Mediated Down-Regulation of Slug.
    Jittreetat T; Shin YS; Hwang HS; Lee BS; Kim YS; Sannikorn P; Kim CH
    Yonsei Med J; 2016 May; 57(3):588-98. PubMed ID: 26996556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
    Zhao L; Yasumoto K; Kawashima A; Nakagawa T; Takeuchi S; Yamada T; Matsumoto K; Yonekura K; Yoshie O; Yano S
    Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
    Zou HY; Li Q; Lee JH; Arango ME; McDonnell SR; Yamazaki S; Koudriakova TB; Alton G; Cui JJ; Kung PP; Nambu MD; Los G; Bender SL; Mroczkowski B; Christensen JG
    Cancer Res; 2007 May; 67(9):4408-17. PubMed ID: 17483355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
    Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
    Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
    Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
    Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.